ArticleBMC gastroenterology2025
Development and validation of predictive models for disease-free survival and overall survival in non-metastatic right-sided colon adenocarcinoma patients based on inflammatory and nutritional indices.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of Metastatic Lymph Node Burden in Colorectal Cancer: A Negative Binomial Regression Analysis.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study developed and validated prognostic nomograms incorporating inflammatory and nutritional biomarkers to predict disease-free survival (DFS) and overall survival (OS) in patients with non-metastatic right-sided colon adenocarcinoma (NRCA).
methodsWe retrospectively analyzed NRCA patients who underwent curative resection and allocated 70% (n = 406) to training cohort and 30% (n = 172) to internal validation cohort. An external cohort from a secondary institution (n = 103) provided independent validation. Optimal thresholds for neutrophil-to-lymphocyte ratio (NLR) and prognostic nutritional index (PNI) were established via X-tile software. Prognostic factors were identified through univariate and multivariate Cox regression analyses, followed by nomogram construction. Model performance was evaluated via Harrell’s concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Survival differences across risk-stratified subgroups were assessed via Kaplan‒Meier analysis. A comparative performance evaluation against tumor-node-metastasis (TNM) staging was conducted.
resultsThe NLR and PNI optimal cutoffs were determined to be 4.6 and 48.8, respectively. Multivariate analysis revealed that age, CEA level, tumor size, perineural invasion, T and N stage, lymph node dissection (≥ 12), chemotherapy, NLR, and PNI were independent predictors of DFS. For OS, significant predictors included age; CEA level; T and N stage; lymph node dissection (≥ 12); NLR; and PNI. The nomograms demonstrated robust discrimination, with C indices for DFS of 0.805 (training), 0.759 (internal validation), and 0.722 (external validation) and for OS of 0.784, 0.729, and 0.719, respectively. Compared with TNM staging, time-dependent ROC analysis revealed superior prognostic accuracy for both endpoints (p < 0.001). The calibration plots revealed excellent agreement between the predicted and observed outcomes, whereas the DCA confirmed the clinical utility of the model. Risk stratification effectively differentiated survival outcomes between subgroups (log-rank p < 0.001). The finalized nomograms are available as web-based tools: DFS ( https://right-sided.shinyapps.io/NRCA/ ) and OS ( https://right-sided.shinyapps.io/NRCAOS/ ).
conclusionThese validated nomograms incorporating NLR and PNI provide enhanced prognostic precision for NRCA patients, offering clinically actionable tools for personalized risk assessment and treatment optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.